Upcoming Webinars Archived Webinars Training Vitals Host A Webinar About Get Updates Contact

Walgreens Terminates Partnership With Blood Test Company, Theranos

XTALKS VITALS NEWS

Blood Test

The tests – which require just a single drop of blood – have already stopped being sold in California.

Share this!

June 14, 2016 | by Sarah Massey, M.Sc.

Tweet: Walgreens ends partnership with #Theranos. http://ctt.ec/C4nBX+

Walgreens has officially ended its partnership with medical laboratories services company, Theranos. The US pharmacy giant is set to close all 40 of the Theranos blood testing centers in its Arizona drugstores.

These locations were the last ones still operating after questions were raised regarding the accuracy of Theranos’ blood test results. The tests – which require just a single drop of blood – have already stopped being sold in California.

Loss of the Walgreens partnership is just the most recent blow to the California-based blood test company. While Theranos does operate its own retail testing centers, the Walgreens locations in Arizona were believed to bring in the majority of its customers.

The Centers for Medicare and Medicaid Services (CMS) are considering banning Theranos founder Elizabeth Holmes from operating a blood testing facility for two years, after federal regulators identified a number of issues at its lab in Newark, California. Theranos is also facing an ongoing Securities and Exchange Commission (SEC) investigation.



“In light of the voiding of a number of test results, and as the Centers for Medicare and Medicaid Services has rejected Theranos’s plan of correction and considers sanctions, we have carefully considered our relationship with Theranos and believe it is in our customers’ best interests to terminate our partnership,” said senior vice president of Walgreens, Brad Fluegel.

Formerly hailed as a Silicon Valley darling, Theranos offered fingerprick blood tests which the company claimed would be more accurate and less expensive than traditional tests. Despite voiding the results of tens of thousands of blood tests, the company has so far only corrected less than one percent of the affected results.

“We are disappointed that Walgreens has chosen to terminate our relationship and remain fully committed to our mission to provide patients access to affordable health information,” said a statement released by Theranos. “Quality and safety are our top priorities and we are working closely with government officials to ensure that we not only comply with all federal regulations but exceed them.”


Keywords: Blood Test, Theranos, Pharmacy


| NEXT ARTICLE | MORE NEWS | BLOGS | VIDEOS | POLLS & QUIZZES | WEBINARS |

Share this with your colleagues!

MORE NEWS
Researchers Identify Role of ApoE4 Gene as Possible Drug Target in Alzheimer’s Disease

September 21, 2017 - A team of neurology researchers at Washington University School of Medicine in St. Louis have found that in the presence of the ApoE4 protein, another protein known as tau forms tangles in the brain which contributes to neuronal damage characteristic of Alzheimer’s disease.

Featured In: Life Science News


New Guidelines Address CAR-T Immunotherapy Toxicities to Prevent Patient Deaths

September 20, 2017 - Clinicians at The University of Texas MD Anderson Cancer Center have published new guidelines in the journal, Nature Reviews Clinical Oncology, which could help in the management of these toxicities.

Featured In: Biotech News, Drug Safety News


Microneedle Skin Patch Could Treat Common Metabolic Disorders

September 19, 2017 - Researchers at Columbia University Medical Center (CUMC) and the University of North Carolina have developed a microneedle skin patch impregnated with a drug capable of converting white fat into calorie-burning brown fat.

Featured In: Medical Device News


LEAVE A COMMENT
 
  
THE XTALKS VITALS INDUSTRY BLOG

Five Reasons Why Toronto is Emerging as a Major Life Sciences Hub

REGISTER FOR THESE WEBINARS

Development and Manufacture of Highly Potent API Drug Products Throughout the Clinical Phases


Innovation through Integration – Providing Next Generation Biomedical Devices and Interconnects


Clinical Payments Case Studies: Improving Efficiency, Cash Management, and Compliance


Why Phase 3 Trials Fail: Oncology Case Studies and Lessons Learned


Copyright © 2016-2017 Honeycomb Worldwide Inc.